RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a ...

Thousands of men living with hormone-sensitive prostate cancer (HSPC) in England and Wales will gain access to abiraterone – both Johnson & Johnson's Zytiga brand and generics – under new guidance ...

RedHill Biopharma ( ($RDHL) ) has provided an update. On December 15, 2025, RedHill Biopharma announced positive in vivo results for opaganib, ...

RedHill Biopharma (RDHL) announced positive in vivo results, indicating that opaganib combined with venetoclax reduces Chronic Lymphocytic ...

For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

The FDA has approved Akeega plus prednisone for adults with deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.

A randomized controlled trial compared coronary artery plaque progression after androgen deprivation therapy using relugolix vs leuprolide in men with prostate cancer.

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

Combining elacestrant with targeted agents produced “clinically meaningful” outcomes for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer who have received at least ...